Seromucinous Cystadenoma Presenting as Endometriosis Complications in a 57-Year-Old Female: A Case Report.

Endometriosis should be considered when a female patient reports symptoms of severe pain/tenderness in the pelvic area associated with a frequent need for urination, bloating, vomiting, or nausea. Clinical suspicion is increased if the patient has a history of endometriosis. However, many patients with endometriosis can be asymptomatic, which is why physicians and providers must keep an open mind and have a broad differential. Examinations that aid in the diagnosis of endometriosis include but are not limited to a pelvic examination, an ultrasound, magnetic resonance imaging (MRI), and an exploratory laparoscopy. In this case study, we present a 57-year-old postmenopausal female patient who presented to her obstetrics and gynecology (OBGYN) physician with hot flashes and an abnormal ultrasound revealing an ovarian cyst. Seventeen years prior, at the age of 40, the patient was found to have endometriosis and endometrial polyps and underwent a left oophorectomy. Due to the patient's history, symptoms, and current scans, it was assumed that the present cyst was a complication of endometriosis. Ultimately, the cyst, right ovarian cyst wall, right fallopian tube, and uterine fibroids were surgically removed and sent to pathology. Upon further review of the patient's pathology reports, it was found that the cyst removed was a seromucinous cyst with focal borderline features.

The relationship between INTEM/HEPTEM coagulation time ratio and heparin plasma concentration in obstetric patients: an exploratory in vitro investigation.

PURPOSE: Unfractionated heparin continues to be one of the main agents used for thromboprophylaxis in obstetrics, which can complicate the placement of neuraxial anesthetics. In this study, we explored the relationship between a point-of-care coagulation test (thromboelastometry) and plasma heparin concentrations in vitro. METHODS: We obtained blood from consenting obstetric patients with uncomplicated pregnancies in their third trimester who were not in labour and had a specific hematocrit range. Blood was processed and analyzed. We added increasing amounts of unfractionated heparin to samples from 0 to 0.3 U·mL-1 in 0.05 U·mL-1 increments to simulate increasing doses of unfractionated heparin. We performed INTEM and HEPTEM testing in parallel with activated partial thromboplastin time (aPTT) testing. We created a model of the relationship between heparin concentration and the INTEM/HEPTEM coagulation time (IH CT) ratio using nonlinear regression. A similar model for aPTT was also created. RESULTS: Seventy-seven patients were included in the study. Only one concentration of heparin was added to blood samples of each patient. At a concentration of 0.05 U·mL-1, the IH CT ratio was less than or equal to 1.1 in 9/11 (82%) samples. Activated partial thromboplastin time was not prolonged (> 35 sec) until a concentration of 0.1 U·mL-1 heparin was added. In all samples, the IH CT ratio was prolonged at a concentration ≥ 0.2 U·mL-1 as measured by thromboelastometry; however, at no concentration of heparin was aPTT prolonged in all samples. CONCLUSION: The point-of-care IH CT ratio may be useful in identifying the presence of little to no heparin activity. Further research is needed to determine if this ratio can predict heparin activity in vivo.

RéSUMé: OBJECTIF: L'héparine non fractionnée demeure l'un des principaux agents utilisés pour la thromboprophylaxie en obstétrique, ce qui peut compliquer la mise en place d'anesthésiques neuraxiaux. Dans cette étude, nous avons exploré la relation entre un test de coagulation au chevet de la patiente (thromboélastométrie) et les concentrations plasmatiques d'héparine in vitro. MéTHODE: Nous avons obtenu du sang de patientes obstétricales consentantes ayant des grossesses non compliquées au cours de leur troisième trimestre qui n'étaient pas en travail et dont l'hématocrite était dans une plage spécifique. Le sang a été traité et analysé. Des quantités croissantes d'héparine non fractionnée ont été ajoutées à des échantillons de 0 à 0,3 U·mL−1 en incréments de 0,05 U·mL−1 pour simuler des doses croissantes d'héparine non fractionnée. Des tests INTEM et HEPTEM ont été réalisés en parallèle avec des tests de temps de thromboplastine partielle activée (aPTT). Un modèle de la relation entre la concentration d'héparine et le ratio temps de coagulation INTEM/HEPTEM (IH CT) a été créé en utilisant une régression non linéaire. Un modèle similaire pour l'aPTT a également été créé. RéSULTATS: Soixante-dix-sept patientes ont été incluses dans l'étude. Une seule concentration d'héparine a été ajoutée aux échantillons de sang de chaque patiente. À une concentration de 0,05 U·mL−1, le ratio IH CT était inférieur ou égal à 1,1 dans 9/11 échantillons (82 %). L'aPTT n'a pas été prolongé (> 35 sec) jusqu'à ce qu'une concentration d'héparine de 0,1 U·mL−1 soit ajoutée. Dans tous les échantillons, le ratio IH CT a été prolongé à une concentration ≥ 0,2 U·mL−1 telle que mesurée par thromboélastométrie; cependant, dans tous les échantillons, aucune concentration d'héparine n'a prolongé l'aPTT. CONCLUSION: Le ratio IH CT au chevet de la patiente peut être utile pour identifier la présence d'une activité d'héparine faible ou nulle. D'autres recherches sont nécessaires pour déterminer si ce ratio peut prédire l'activité héparinique in vivo.

Impact of fibrinogen and prothrombin complex concentrate on clotting time in a model of obstetric hemorrhage.

STUDY OBJECTIVE: Determine the impact of varying doses of fibrinogen concentrate and 4-factor prothrombin complex concentrate on clotting time as measured by thromboelastometry in an in-vitro model of dilutional coagulopathy. DESIGN: In-Vitro Study. SETTING: Tertiary academic center. PATIENTS: 31 healthy term singleton gestation patients. INTERVENTIONS: Blood was analyzed and diluted 95% with crystalloid. Washed red blood cells were added to simulate red blood cell transfusion. Two levels of fibrinogen repletion were then added to samples to simulate fibrinogen repletion in massive transfusion. Finally, 4-factor prothrombin complex concentrate (10 U/kg, 15 U /kg, or 25 U/kg) adjusted for body weight and estimated blood volume was added. MEASUREMENTS: Samples were analyzed by thromboelastometry, and the main outcome was a FIBTEM clotting time > 80s. MAIN RESULTS: FIBTEM clotting times were prolonged after dilution. After repletion with fibrinogen and prothrombin complex concentrates 7/31 (22.5%) of samples had a prolonged FIBTEM clotting time (> 80s) in the 50% fibrinogen repletion arm and 0 (0%) had a prolonged clotting time in the 100% fibrinogen repletion arm. FIBTEM clotting times approached their baseline levels at each dose of prothrombin complex concentrate. Median clotting time in the 100% fibrinogen repletion arm was under 80s prior to the administration of prothrombin complex concentrate. CONCLUSIONS: Commonly cited doses for prothrombin complex concentrates in hemorrhage might be too high for the obstetric patient. After fibrinogen correction alone, several samples required no further correction, highlighting the importance of frequent testing at the point of care. Limitations of this study include the in vitro study design and ability to directly apply findings to patient care. Further studies are needed to elucidate the ideal dose of prothrombin complex concentrate for obstetric hemorrhage. TWEETABLE ABSTRACT: Fibrinogen concentrate and low dose 4-factor PCC corrected coagulopathy in in-vitro obstetric hemorrhage.

The impact of crystalloid versus colloid on coagulation as measured by thromboelastometry in term parturients: an in vitro study.

OBJECTIVE: A pilot study to examine the impact of crystalloid versus albumin hemodilution in vitro on coagulation using thromboelastometry in pregnant patients. METHODS: This prospective, observational pilot study included seventy-six pregnant patients at term (≥37 weeks) without history of bleeding or clotting disorder or on anticoagulation. Blood was collected and diluted with either Plasma-Lyte or albumin at the following levels: 0%, 20%, 25%, 30%, 35%, 40%, 45%, 55%, 60%, 65%, 70%, 75%, 80%. Thromboelastometry was performed to assess for coagulation changes. RESULTS: There was a small, statistically significant difference in the FIBTEM A5 between the Plasma-Lyte and albumin samples. However, the predicted probability of coagulopathy, using FIBTEM A5 less than 12 mm, was not different between the groups at any dilution. There was no difference in EXTEM clotting time at low-moderate levels of hemodilution. At dilutions above 40%, the albumin group had a significantly greater prolongation in clotting time compared to the Plasma-Lyte group. CONCLUSION: When albumin is used at low-moderate levels of hemodilution in vitro in parturients there is no additional risk of coagulopathy compared to hemodilution with crystalloid. Given that colloids are frequently used to restore intravascular volume during massive hemorrhage, these results support that during early stages of hemorrhage, albumin may not contribute to additional coagulopathy beyond that of hemodilution, although further in vivo studies are needed.

The effects of hemodilution on coagulation in term parturients: an in vitro study utilizing rotational thromboelastometry.

OBJECTIVE: To examine the impact of hemodilution on components of blood coagulation using rotational thromboelastometry (ROTEM®) in term parturients. METHODS: This is a prospective, observational pilot study including 35 healthy, parturients at term (≥37 weeks) without history of bleeding or clotting disorder or on medication affecting coagulation. Venous blood samples were collected and divided into specimen tubes to generate varying degrees of hemodilution with Plasma-Lyte (0%, 20%, 25%, 30%, 35%, 40%, 45%, 55%, 60%, 65%, 70%, 75%, 80%). ROTEM® was performed to assess for coagulation changes. RESULTS: EXTEM (extrinsically activated assay) clotting time (CT) became prolonged at 65% hemodilution and above, and the median CT was in the coagulopathic range (>80 s) at a dilution of 80%. FIBTEM (extrinsically activated assay with platelet inhibitor) amplitude at 5 min (A5) began to diminish at 35% hemodilution, with the median A5 in the coagulopathic range (<12 mm) at 55% hemodilution. The area under the curve (AUC) for EXTEM and FIBTEM consistently declined as hemodilution increased. Greater decreases in FIBTEM AUC were seen compared to EXTEM AUC, with the ratio of FIBTEM:EXTEM AUC at each dilution demonstrating a statistically significant difference from baseline. CONCLUSION: All thromboelastometry values demonstrated a hypocoagulable trend as hemodilution increased. However, the samples analyzed by the FIBTEM assay trended toward a coagulopathy at a lower degree of hemodilution compared to the EXTEM assay. As FIBTEM tests analyze the role of fibrinogen in hemostasis and EXTEM tests analyze the role of platelets, our findings suggest that platelets may be able to withstand higher degrees of hemodilution before impairing hemostasis compared to fibrinogen. These findings support the growing body of literature that in early stages of severe obstetric hemorrhage, the prioritization of fibrinogen replacement may be critical in preventing further coagulopathy.

Baseline parameters for non-activated rotational thromboelastometry tests with and without heparinase in healthy pregnant women at term gestation.

OBJECTIVE: To determine the normal values for non-activated thromboelastometry parameters among pregnant women. DESIGN: Prospective, observational study. SETTING: Tertiary care hospital. PATIENTS: Non-laboring women at term gestation without history of bleeding or clotting disorder or anticoagulation use. INTERVENTIONS: Venous blood samples were collected and ROTEM® was performed using NATEM and NaHEPTEM assays. MEASUREMENTS: Reference ranges were derived by calculating 2.5 and 97.5 percentiles for the following parameters: clotting time (CT), clot formation time (CFT), amplitude at 10 (A10) and 20 min (A20), alpha angle, maximum clot firmness (MCF), and lysis index at 30 (LI30) and 60 min (LI60). The NATEM/NaHEPTEM CT ratio was calculated to determine the baseline ratio in term pregnant women. MAIN RESULTS: 146 women were screened and 120 were enrolled. The median age was 34 years [31-36], median gestational age was 39.1 weeks [38.3-39.3], and median parity was 1 [0-2]. Median pre-delivery platelet and hematocrit levels were within the normal ranges. The reference ranges for NATEM parameters were: CT (232-759 (s)), CFT (69-243 (s)), alpha angle (50-77 (°)), A10 (44-69 (mm)), A20 (54-75 (mm)), MCF (57-77 (mm)), LI30 (100-100 (%)), LI60 (90-100 (%)). The reference ranges for NaHEPTEM parameters were: CT (224-717 (s)), CFT (66-210 (s)), alpha angle (53-77 (°)), A10 (44-67 (mm)), A20 (55-73 (mm)), MCF (58-74 (mm)), LI30 (99-100 (%)), LI60 (90-100 (%)). The NATEM to NaHEPTEM CT ratio reference range was 0.73-1.3. CONCLUSIONS: This study is the first to our knowledge to report reference ranges for non-activated ROTEM® tests with and without heparinase in non-laboring term pregnant women. These reference ranges may serve as a baseline comparison and may be useful for future research on anticoagulation management in pregnancy.

Thromboelastometry-guided neuraxial anesthesia in a parturient with severe thrombocytopenia due to large granular lymphocytic leukemia.

Severe thrombocytopenia (platelet count <50 000/µl) in pregnancy is uncommon and is generally considered a contraindication to neuraxial anesthesia. We present a case of a parturient who presented with severe thrombocytopenia secondary to bone marrow failure. After receiving platelet and cryoprecipitate transfusions to correct coagulopathy as verified by thromboelastometry, neuraxial anesthesia was safely utilized.